- Company has received UK Continuing Professional Development
("CPD") accreditation for its global education platform, Khiron
Academy
- UK medical professionals may now earn CPD credits through
Khiron's medical cannabis education program
- The Company has entered into a strategic partnership with
Cellen Therapeutics, a leader in digital healthcare in the UK, to
increase patient access via medical cannabis education
- As a leading international medical cannabis educator, nearly
1,000 medical professionals in Latin
America and the United
Kingdom have registered for, or completed, Khiron Academy
training
TORONTO, April 13, 2021 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce it has received
UK Continuing Professional Development ("CPD") accreditation for
Khiron Academy, the Company's global medical cannabis education
platform.
Khiron has entered into a strategic partnership with Cellen
Therapeutics, a leader in digital healthcare in the UK
Additionally, following its accreditation, the Company has
entered into a strategic partnership with Cellen Therapeutics, a
leader in digital healthcare in the UK and fellow founding member
of Project Twenty21, to increase patient access through medical
cannabis education initially. Khiron Academy will be made available
to prescribers in the UK that have registered with Cellen's
MedCanHub, an emerging education portal. Cellen is market leader,
widely recognized for also launching the UK's first digital pain
clinic, Leva.
Tejinder Virk, President of
Khiron Europe, commented, "Over the last year, Khiron has seen a
direct correlation between physician education and patient access.
With Khiron Academy's CPD accreditation and through our strategic
partnership with Cellen Therapeutics, we are positioned to reach a
growing number of medical professionals, and in turn, provide
patients with greater access to medical cannabis products."
Eric Bystrom, CEO of Cellen
commented, "We are pleased to be joining forces with Khiron on
educating prescribing specialists in the UK. Khiron is a clear
global leader in medical cannabis education. We share common values
in improving patient lives by educating doctors and optimizing the
standard of medical care. Our aim is to create a practical guide
for responsibly prescribing patients with safe and efficacious
medical cannabis products."
In the UK, Khiron continues to leverage educational materials
developed by the Company to train medical professionals in
Latin America, along with clinical
data from thousands of Khiron patients. In addition to Cellen's
MedCanHub (accessible to medical professionals at
https://medcanhub.cellenhealth.com/), Khiron Academy is available
to members of the Medical Cannabis Clinicians Society (MCCS) and
core to the training of prescribing specialists for Project
Twenty21, a 20,000-patient observational study backed Drug Science
in UK.
To date, the Company has trained nearly 1000 medical
professionals in Latin America and
the UK. Over the last year, physicians trained by Khiron in
Latin America have issued over
13,000 prescriptions, with a compound monthly growth rate of nearly
50%. Khiron Academy will be a platform for sharing the Company's
clinical expertise, in conjunction with clinical data arising from
Khiron's wholly-owned clinics in LatAm.
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading medical cannabis provider in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Colombia, Peru, Germany
and the United Kingdom, and is
positioned to commence sales in Mexico, Germany and Brazil in 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing unit launched the
first branded CBD skincare brand in Colombia, with KuidaTM now marketed
in multiple jurisdictions in Latin
America, the US and United
Kingdom. The Company is led by Co-founder and Chief
Executive Officer, Alvaro Torres,
together with an experienced and diverse executive team and Board
of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
Investor Contact:
Paola
Ricardo
E: investors@khiron.ca
T: +1 (647) 556-5750
Media Contact:
Peter
Leis
Europe Communications Manager
E: pleis.ext@khiron.ca
Khiron Europe:
Tejinder
Virk
Europe President
E: tvirk@khiron.ca
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-receives-accreditation-for-uk-medical-cannabis-education-and-partners-with-uks-cellen-therapeutics-to-improve-clinician-education-301267784.html
SOURCE Khiron Life Sciences Corp.